Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice
Open Access
- 14 August 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-16
Abstract
Antibodies have been explored extensively as a potential therapeutic for Alzheimer’s disease, where amyloid-β (Aβ) peptides and the tau protein deposit in patient brains. While the major focus of antibody-based therapy development was on Aβ, arguably with limited success in clinical trials, targeting tau has become an emerging strategy, possibly extending therapies to dementias with isolated tau pathology. Interestingly, low titres of autoantibodies to pathological tau have been described in humans and transgenic mouse models, but their pathophysiological relevance remained elusive. Here, we used two independent approaches to deplete the B-cell lineage and hence antibody formation in human P301S mutant tau transgenic mice, TAU58/2. TAU58/2 mice were either crossed with the B-cell-deficient Ighm knockout line (muMT−/−) or treated with anti-CD20 antibodies that target B-cell precursors. In both models, B-cell depletion significantly reduced astrocytosis in TAU58/2 mice. Only when B-cells were absent throughout life, in TAU58/2.muMT−/− mice, were spatial learning deficits moderately aggravated while motor performance improved as compared to B-cell-competent TAU58/2 mice. This was associated with changes in brain region-specific tau solubility. No other relevant behavioural or neuropathological changes were observed in TAU58/2 mice in the absence of B-cells/antibodies. Taken together, our data suggests that the presence of antibodies throughout life contributes to astrocytosis in TAU58/2 mice and limits learning deficits, while other deficits and neuropathological changes appear to be independent of the presence of B-cells/antibodies.Keywords
Funding Information
- National Health and Medical Research Council (1132524, 1143848, 1081916)
- Australian Research Council (DP150104321, DP170100843, DP170100781)
This publication has 44 references indexed in Scilit:
- Genomic Analysis of Reactive AstrogliosisThe Journal of Neuroscience, 2012
- Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic MicePLOS ONE, 2011
- Passive Immunization with Anti-Tau Antibodies in Two Transgenic ModelsJournal of Biological Chemistry, 2011
- Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease modelsProceedings of the National Academy of Sciences, 2010
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin ReceptorMolecular Pharmaceutics, 2009
- Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjectsNeuroscience Letters, 2006
- Post-translational modifications of tau protein in Alzheimer’s diseaseJournal of Neural Transmission, 2004
- Diagnosis of systemic lupus erythematosus. Importance of antinuclear antibody titers and peripheral staining patternsArchives of Dermatology, 1975